PriceTargets.com logo

NASDAQ:BLU - BELLUS Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.62
  • Forecasted Upside: 115.96 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$3.99 As of 03/4/2021 03:31 PM ET
▼ -0.19 (-4.55%)
1 month | 3 months | 12 months
Get New BELLUS Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BLU and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLU

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$8.62
▲ +115.96% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for BELLUS Health in the last 3 months. The average price target is $8.62, with a high forecast of $12.00 and a low forecast of $6.00. The average price target represents a 115.96% upside from the last price of $3.99.
Buy
The current consensus among 9 investment analysts is to buy stock in BELLUS Health.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/3/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/29/2021Royal Bank of CanadaInitiated CoverageOutperform$8.00High
i
11/18/2020Evercore ISIInitiated CoverageOutperform$12.00High
i
11/12/2020Lifesci CapitalReiterated RatingOutperformMedium
i
Rating by S. Slutsky at Lifesci Capital
8/14/2020HC WainwrightLower Price TargetBuy$28.00 ➝ $10.00Medium
i
Rating by A. Fein at HC Wainwright
8/13/2020Ci CapitalReiterated RatingBuy$7.00Medium
i
7/7/2020Robert W. BairdLower Price TargetOutperform$14.00 ➝ $6.00High
i
7/7/2020GuggenheimDowngradeBuy ➝ NeutralHigh
i
7/6/2020MackieDowngradeBuy ➝ Hold$8.70High
i
6/26/2020HC WainwrightInitiated CoverageBuy$28.00High
i
Rating by A. Fein at HC Wainwright
3/5/2020CowenReiterated RatingBuyMedium
i
9/30/2019JBL AdvisorsInitiated CoverageBuyMedium
i
9/30/2019CowenInitiated CoverageOutperformHigh
i
9/30/2019GuggenheimInitiated CoverageBuy$12.00High
i
9/30/2019Jefferies Financial GroupInitiated CoverageBuy$20.00High
i
9/6/2019Bloom BurtonReiterated RatingBuyLow
i
Rating by D. Martin at Bloom Burton
(Data available from 3/4/2016 forward)
BELLUS Health logo
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.
Read More

Today's Range

Now: $3.99
$3.80
$4.21

50 Day Range

MA: $3.78
$3.13
$4.56

52 Week Range

Now: $3.99
$2.01
$12.03

Volume

250,178 shs

Average Volume

1,721,838 shs

Market Capitalization

$312.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.42

Frequently Asked Questions

What sell-side analysts currently cover shares of BELLUS Health?

The following equities research analysts have issued stock ratings on BELLUS Health in the last twelve months: Ci Capital, Cowen Inc, Evercore ISI, Guggenheim, HC Wainwright, Lifesci Capital, Mackie, Robert W. Baird, Royal Bank of Canada, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for BLU.

What is the current price target for BELLUS Health?

6 Wall Street analysts have set twelve-month price targets for BELLUS Health in the last year. Their average twelve-month price target is $8.62, suggesting a possible upside of 106.1%. Evercore ISI has the highest price target set, predicting BLU will reach $12.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $6.00 for BELLUS Health in the next year.
View the latest price targets for BLU.

What is the current consensus analyst rating for BELLUS Health?

BELLUS Health currently has 2 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BLU will outperform the market and that investors should add to their positions of BELLUS Health.
View the latest ratings for BLU.

What other companies compete with BELLUS Health?

Other companies that are similar to BELLUS Health include Rhythm Pharmaceuticals, Pliant Therapeutics, Mersana Therapeutics, Indivior, Cassava Sciences, Arcturus Therapeutics, Northwest Biotherapeutics, Avid Bioservices, Omeros, Theravance Biopharma, Constellation Pharmaceuticals, Annexon, Keros Therapeutics, Repare Therapeutics and BioXcel Therapeutics.

How do I contact BELLUS Health's investor relations team?

BELLUS Health's physical mailing address is 275 ARMAND-FRAPPIER BLVD., LAVAL A8, H7V 4A7. The company's listed phone number is 450 680 4500 and its investor relations email address is [email protected] The official website for BELLUS Health is www.bellushealth.com.